Impact of different P2Y12 inhibitors in acute coronary syndrome patients with severe chronic kidney disease: insights from the CORALYS registry
Anno:
2024
BACKGROUND: The impact of the most potent P2Y12i ticagrelor and prasugrel after acute coronary syndrome in patients with chronic kidney disease (CKD) remains unclear. Indeed, this condition is associated to both higher thrombotic and hemorragic risk, as a consequence newer P2Y12i are seldom used. Most evidence comes from real-world…